PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
0.97
0.5–0.75x AXSM's 1.57. Martin Whitman would question if short-term obligations are sufficiently covered.
0.97
0.5–0.75x AXSM's 1.51. Martin Whitman might be concerned about coverage if a crisis hits.
0.00
Below 0.5x AXSM's 0.89. Michael Burry could foresee potential liquidity shocks if times get tough.
-2.29
Negative interest coverage while AXSM shows 20.02. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.